El precio de los medicamentos y la paradoja de la transparencia
La divulgación de los datos puede elevar mucho el importe a pagar por los fármacos, retrasar o impedir que se comercialicen en nuestro país y dejar a los pacientes sin los tratamientos que necesitan
On June 25, an unusual and fortunate agreement between the PSOE, PP, and Sumar allowed the Health Commission of the Congress of Deputies to approve a modification of the Medicines Law. This change aims to protect the confidentiality of agreements on publicly funded drug financing, including actual prices paid and supply contracts.
To ensure transparency, authorities involved in competition and taxation can access all this information. The Ministry of Health is also required to publish both individual and aggregated data that is accessible, excluding critical points of the agreements. This new provision became law by the end of the previous month, seemingly concluding lengthy complaints and lawsuits currently pending two cassation appeals to the Supreme Court involving organizations such as Civio and the Council for Transparency and Good Government against the Ministry of Health.
Written by urgent.news from El Pais Economia's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
